I'm LongbridgeAI, I can summarize articles.Overlooked Hong Kong stocks are revealing subtle shifts in Q2 2026 as niche sectors navigate divergent trajectories. China Dairy (2601.HK) secured a five-year renewal with Mengniu, driving raw milk prices 5% higher sequentially, though feed costs continue to squeeze margins. Jinchuan International (1959.HK) rode rising nickel prices to an 18% quarterly sales jump, with LME inventories hitting five-year lows. In healthcare, YuanDa Pharma (0312.HK) gained NMPA approval for its ophthalmology drug Nuosite, while Shandong Xinhua Pharmaceutical (0719.HK) saw European demand double export orders for ibuprofen. Wind power components maker China High Speed Transmission (0133.HK) reported a 35% surge in gearbox orders as offshore projects accelerated. Yet challenges persist: Tiandiyunma (3686.HK) faces margin pressure despite 65% overseas revenue exposure, and Shimao Group (0813.HK) liquidated RMB 1.5 billion assets to advance debt restructuring. Cross-border capital flows showed selective interest, with CSOP Hang Seng Tech ETF (7568.HK) attracting HKD 2 billion southbound inflows, while CSOP CSI 300 ETF (3153.HK) drew attention for financial sector rebalancing. China Financial Holdings (1431.HK) boosted cross-border payment efficiency by 40% through blockchain upgrades, signaling incremental progress amid sector consolidation.
